(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 September 2021 (16.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/181262 A1

(51) International Patent Classification:
*A61K 9/16* (2006.01) *A61K 9/28* (2006.01)
*A61K 9/20* (2006.01) *A61K 31/00* (2006.01)

(21) International Application Number:
PCT/IB2021/051942

(22) International Filing Date:
09 March 2021 (09.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202011010072 09 March 2020 (09.03.2020) IN

(71) Applicant: **ALMENDRO PROPERTIES AND TRADING LLP** [IN/IN]; 1st Floor, Apeejay Chambers, 5 Wallace, Fort Mumbai, Mumbai City, Maharashtra 400001 (IN).

(72) Inventors: **BERLIA, Sushma Paul**; S-361, Panchsheel Park, Outer Ring Road, New Delhi, Delhi 110017 (IN). **BERLIA, Nishant**; 1, Tughlak Lane, New Delhi, Delhi 110011 (IN). **SINGH, Gurvinder**; WZ 304, Lane-17, Shiv Nagar, Near B2, Janak Puri, New Delhi, Delhi 110058 (IN). **BHANDARI, Sunder Singh**; B-297, Sector 20, Noida, Uttar Pradesh 201301 (IN). **DIWAN, Anupama**; School of Pharmaceutical Sciences, Apeejay Stya University, Sona - Palwal Road, Sona, Haryana 122103 (IN).

(74) Agent: **BHASIN, Gayatri** et al.; Subramaniam & Associates, 7th Floor, M3M Cosmopolitan, Sector 66, Golf Course Extension Road, National Capital Region, Gurugram 122001 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: CONTROLLED RELEASE FORMULATIONS COMPRISING DROTAVERINE OR SALT THEREOF





Figure 1

(57) Abstract: The present invention provides controlled release formulations comprising Drotaverine or salt thereof or similar active agents which are prone to oxidative/hydrolytic degradation. The invention provides once or twice a day controlled release formulations of Drotaverine or salt thereof which avoids fluctuations of plasma levels, reduces pill burden and side effects owing to simplified dosage schedule, thereby improving patient compliance. The invention also provides methods of preparation of controlled release formulations of Drotaverine or salt thereof. The invention further provides controlled-release formulations of Drotaverine or salt thereof for treating at least one symptom of gastrointestinal, biliary, urological and gynecological disorders characterized by spastic conditions of smooth muscles in a subject.

WO 2021/181262 A1

*[Continued on next page]*

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*